Roche’s Ocrevus more effective than Merck’s Rebif, company claims

Roche has announced new results from the Phase III studies of investigational medicine Ocrevus (ocrelizumab) studying relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The data will be presented during the 32nd congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) this week in London.
read more